Risk Of Developing Liver Cancer After HCV Treatment

Wednesday, April 26, 2017

International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates

International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates
Terrault, Norah A. MD, MPH1; McCaughan, Geoff W. MD, BS, PhD2; Curry, Michael P. MD3; Gane, Edward MD4; Fagiuoli, Stefano MD5; Fung, James Y. Y. MD6; Agarwal, Kosh MD7; Lilly, Les MD8; Strasser, Simone I. MBBS, MD9; Brown, Kimberly A. MD10; Gadano, Adrian MD11; Kwo, Paul Y. MD12; Burra, Patrizia MD13; Samuel, Didier MD14; Charlton, Michael MD15; Pessoa, Mario G. MD16; Berenguer, Marina MD17

Transplantation: May 2017 - Volume 101 - Issue 5 - p 945–955
doi: 10.1097/TP.0000000000001708

An expert panel from ILTS reviews the approach to management of HCV in the transplant recipient in the era of direct-acting anti-virals. Considerations range from preemption of recurrence to the treatment of fibrosing cholestatic hepatitis

Article

Full Text Articles
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading full text articles about the treatment and management of hepatitis C. A link to the above consensus statement was provided by Henry E. Chang.

No comments:

Post a Comment